Search Results
You searched for "Merck" ( 317 results )
-
Merck completes expansion of OLED facilities in Pyeongtaek
Merck Korea, the local subsidiary of the German science and technology giant, said Thursday that it has completed expansion work of its local production plant in Pyeongtaek, Gyeonggi Province. In October 2020, the company announced plans to invest 20 million euros ($21 million) into expanding facilities at the plant to produce key materials for organic light-emitting diode displays that had been imported from Germany. “We can now quickly respond to customer requests and demands in Asia
Technology June 9, 2022
-
Standigm Signs MOU with Merck Korea for AI drug Discovery Research
- Merck's retrosynthesis AI software SYNTHIA™ accelerates Standigm's synthesis capability SEOUL, South Korea, June 1, 2022 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Understanding (MOU) with Merck Korea, for AI-based drug discovery research. The MOU signing took place on May 30 at the headquarters of Standigm, attended by Sojeong Yun, CEO of Standigm, and S
PR Newswire June 1, 2022
-
Biocytogen Enters into Antibody Agreement with Merck
BEIJING, April 29, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) announced that it has entered into an evaluation and option agreement with Merck to grant them a sole license to evaluate Biocytogen's proprietary antibodies against at least three distinct targets with an option to acquire some of the assets at a later date for therapeutic product development for all uses worldwide. Under the agreement, Biocytogen will provide Merck antibodies directe
PR Newswire April 29, 2022
-
DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER COMPOUNDS AND DRUG DELIVERY TECHNOLOGIES
Pre-clinical & clinical exploratory poster presentations to highlight oncology results with Debio 0123, xevinapant, and Multilink™ technology for antibody drug conjugates LAUSANNE, Switzerland, April 14, 2022 /PRNewswire/ -- Debiopharm, (www.debiopharm.com/debiopharm-international/) an oncology and infectious disease focused biopharmaceutical company based in Switzerland, today announced data releases on 3 investigational products including Debio 0123 (Selective WEE1 inhibitor), cli
PR Newswire April 14, 2022
-
South Korea looks to end social distancing once and for all
Social distancing may come to a complete end in South Korea in two weeks’ time, according to top officials, over prospects that the ongoing omicron wave is leveling off and receding. Prime Minister Kim Boo-kyum said during a government COVID-19 meeting Friday that there would be “a bold shake-up of the remaining social distancing practices” that are due to expire on April 17. In a news briefing held the same day Minister of Health and Welfare Kwon Deok-cheol said the countr
Social Affairs April 3, 2022
-
Biocytogen Expands Global Footprint with the Opening of Biocytogen Europe Innovation Center in Germany
BEIJING, March 28, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter referred to as "Biocytogen") announced the opening of the Biocytogen Europe Innovation Center (BEIC) in Heidelberg, Germany. Local government representatives, clinical experts, and colleagues and collaborators from multi-national companies made speeches at the opening ceremony. Dr. Vivian Tian, Head of BEIC, hosted the event, and introduced Biocytogen's history, pipeline, and technology
PR Newswire March 28, 2022
-
Amid Paxlovid scarcity, Korea looks for alternatives
South Korea is looking to bring in alternative therapies amid a shortage of Paxlovid, the COVID-19 antiviral pill from Pfizer. The only antibody drug on the market here, Celltrion’s Regkirona, was suspended from use a month ago after evidence emerged that it was ineffective against omicron. Being distributed from Saturday is Merck’s antiviral pill Lagebrio, whose approval here was delayed until Wednesday, nearly four months since the company applied for emergency use review in No
Social Affairs March 25, 2022
-
S. Korea’s daily COVID-19 cases rebound to nearly 500,000
South Korea added nearly 500,000 daily COVID-19 cases during the 24 hours of Tuesday, pushing the country’s accumulated figure over the 10 million mark. According to the Korea Disease Control and Prevention Agency, the country’s daily COVID-19 cases reached 490,881, the second-highest daily tally, after 621,205 cases reported Thursday last week. The country’s accumulated caseload surpassed 10,427,247, which accounts for around 20 percent of the country’s total populat
Social Affairs March 23, 2022
-
S. Korea‘s daily COVID-19 cases fall below 300,000 for the first time in 10 days
South Korea‘s daily COVID-19 infections fell below 300,000 for the first time in 10 days on Sunday, prompting the authorities to speculate that the worst may be over. According to the Korea Disease Control and Prevention Agency, the country added 209,169 new COVID-19 infections on Sunday. The country’s total caseload came to 9,582,815. South Korea’s daily COVID-19 cases have been dropping for four straight days since the country reached an all-time high of 621,281 COVID-19
Social Affairs March 21, 2022
-
Genome and Company announces Clinical Trial Collaboration with MSD to evaluate 'GEN-001' in combination of KEYTRUDA® (pembrolizumab) in phase 2 clinical trial in biliary tract cancer patients
SEOUL, South Korea, March 4, 2022 /PRNewswire/ -- Genome and Company (KOSDAQ: 314130, CEO∙CTO: Jisoo Pae∙Hansoo Park), a leading global microbiome anti-cancer drug development company, announced it has entered into a first Clinical Trial Collaboration and Supply Agreement (CTCSA) with MSD (a tradename of Merck & Co., Inc., Kenilworth, N.J., USA). Upon the execution of the agreement, Genome and Company will conduct a phase 2 clinical trial to evaluate the safety and efficacy of its immuno
PR Newswire March 4, 2022
-
PharmAbcine Announces Last Patient Last Visit in its Phase Ib mTNBC Combination Trial
DAEJEON, South Korea, Feb. 25, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the completion of last patient last visit in its Phase Ib combination trial for mTNBC (metastatic Triple-Negative Breast Cancer) patients in Australia. The clinical study, which had the first patient dosed in December 2018, evaluated the safety and clinical efficacy of ol
PR Newswire Feb. 25, 2022
-
HanAll Biopharma Appoints Almira Chabi as Chief Medical Officer and Chief Development Officer
SEOUL, South Korea, Feb. 21, 2022 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS) announced today the appointment of Almira Chabi, M.D. as Chief Medical Officer and Chief Development Officer at HanAll Pharmaceutical International (HPI), a U.S. entity wholly owned by HanAll Biopharma, to strengthen its R&D capability. "We are extremely pleased to welcome Dr. Chabi as Chief Medical and Development Officer. Dr. Chabi will bring invaluable expertise and leadership to ou
PR Newswire Feb. 21, 2022
-
Leapstack Raised Nearly 150 Million Yuan in Series C Round Financing, Catalyzing Transformation of Intelligent Risk Control in Healthcare Insurance
SHANGHAI, Jan. 14, 2022 /PRNewswire/ -- Recently, Shanghai Leapstack Technology Co., Ltd. (hereinafter referred to as Leapstack), an insurtech company, announced that it had raised a Series C round of 150 million yuan. This round of fundraising was led by Legend Capital, followed by Peakview Capital, GF Qianhe Investment and Huazhi Capital, with Mountain View Capital acting as the fundraising consultant. In recent years, insurtech companies are embracing a more "automated" future wit
PR Newswire Jan. 14, 2022
-
Daily infections below 4,000 for 5th day amid tightened curbs
South Korea's daily coronavirus cases stayed below 4,000 for the fifth consecutive day Tuesday amid tightened antivirus restrictions, but concerns linger over a possible resurgence due to the continued spread of the omicron variant. The country added 3,097 new COVID-19 infections, including 2,813 local infections, raising the total caseload to 670,483, according to the Korea Disease Control and Prevention Agency (KDCA). The country reported 43 more COVID-19 deaths, raising the death toll to 6,
Social Affairs Jan. 11, 2022
-
COVID-19 antiviral pills to arrive in S. Korea next week: PM
Antiviral COVID-19 pills will arrive in South Korea next week, Prime Minister Kim Boo-kyum said Friday. "We will make sure they can be used swiftly in the medical field," Kim said during a COVID-19 response meeting in Seoul. The government has so far secured oral COVID-19 drugs for around 1 million patients. The country signed a prepurchase contract with US drug giant Pfizer Inc. for its Paxlovid pill for 762,000 patients. It also inked a deal with MSD, a subsidiary of US drugmaker
Politics Jan. 7, 2022
-
Korea locks in COVID-19 pills for 1m people. Here’s what to know
South Korea has bought an additional 400,000 courses of Paxlovid, the COVID-19 antiviral pills developed by Pfizer, health officials said Wednesday evening. With the latest purchase, the country has secured enough oral treatments for 1 million people in total -- Pfizer’s for 762,000 people, and the rest from Merck. “Adding pills to our treatment protocol will help stabilize and expand the at-home COVID-19 care scheme, a key pillar of our return to normal,” the Korea Disease C
Social Affairs Jan. 6, 2022
-
Korea wants to coexist with COVID-19 in 2022
With vaccines aplenty and new therapies on the way, South Korea envisions to have less social distancing and more freedom in 2022. In a news briefing Thursday, Vice Minister of Health and Welfare Yoo Geun-heag said with the rise of the omicron variant, “when the pandemic will come to an end has become more unpredictable than ever.” Still, Korea will “strive to make headway toward normalcy carefully,” he said. The government laid out how the country will navigate thro
Social Affairs Dec. 30, 2021
-
Korea approves Pfizer oral drug
An oral drug for COVID-19 is likely to become available via prescription from late January, following the Food and Drug Ministry’s decision Monday to issue emergency authorization for Paxlovid, Pfizer’s oral pill for COVID-19. The announcement came five days after the Korea Disease Control and Prevention Agency requested emergency authorization of the drug manufactured by the global drug giant. “As the number of COVID-19 patients and those in serious condition has been i
Social Affairs Dec. 27, 2021
-
S. Korea begins review of Pfizer's oral COVID-19 pill
South Korea's drug safety agency said Wednesday that it has begun reviewing an emergency authorization of US drug giant Pfizer Inc.'s oral drug to treat COVID-19. Paxlovid is the antiviral pill for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalization or death, according to Pfizer and the Ministry of Food and Drug Safety. If authorized, Paxlovid would be the first oral antiviral of its kind in South Korea. The drug candidate is a protease inhibitor antivi
Social Affairs Dec. 22, 2021
-
[Herald Interview] As pandemic takes grim turn, drug minister says Korea to be better armed against COVID-19
OSONG, North Chungcheong Province -- South Korea’s Minister of Food and Drug Safety Kim Ganglip says his 30 years of office in public health has prepared him to serve the country during an unprecedented public health crisis. As the third pandemic year dawns and omicron darkens prospects, the minister said fresh weapons against the pandemic are coming. The Korea Herald spoke with Kim on Monday afternoon at his office in Osong, North Chungcheong Province, about some of the mo
Social Affairs Dec. 8, 2021
Most Popular
-
1
Seoul vows action over Naver's Line, Yahoo dispute
-
2
[KH Explains] Hyundai Motor’s plan for new landmark keeps hitting bumps
-
3
[Grace Kao] American racism against Stray Kids
-
4
Key S. Korean, USFK special operations officials to hold rare meeting amid NK threats
-
5
Samsung doubles down on Vietnam
-
6
In Beijing, S. Korean top diplomat aims to jumpstart ties with China
-
7
NewJeans' members' parents complained to Hybe, email shows
-
8
Controversy brews over shakeup of prosecutors amid probe of first lady
-
9
Suspect behind murder of Korean tourist in Pattaya arrested
-
10
Prosecutors summon pastor involved in Dior bag scandal